The fact that migraine therapy is changing is also reflected in the recent publication of the updated S1 guideline “Treatment of migraine attacks and prophylaxis of migraine”. Although triptans are still the standard medication for treating acute migraine attacks, new active ingredients are expanding the treatment arsenal. Progress has also been made in migraine prophylaxis – for example, two new oral CGRP receptor antagonists have established themselves as treatment alternatives. These are just some of the innovations that should contribute to optimized care for migraine patients.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
- InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
You May Also Like
- Osteoporosis
Risk-stratified therapy with osteoanabolic agents improves outcomes
- "Swiss Health Care Atlas"
New indicator: medication for weight regulation
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- Treatment of pancreatitis: current study data
How can the risk-benefit profile be improved?
- Prurigo and PN
Anti-inflammatory antipruritic therapy improves quality of life
- Pathophysiology, clinical significance and therapeutic consequences
Eosinophils in asthma
- Urothelial carcinoma
Perioperative innovations and organ-preserving strategies
- Artificial intelligence